GSK's Duchene drug data boost rival
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has released the first data from any placebo-controlled study of drisapersen in Duchene muscular dystrophy (DMD) patients. DMD rival Sarepta Therapeutics saw a boon to its share price as a result.